Abstract NPM1 mutations, the most frequent molecular alterations in acute myeloid leukemia (AML), have become important for risk stratification and treatment decisions for patients with normal karyotype AML. Rapid screening for NPM1 mutations should be available shortly after diagnosis. Several methods for detecting NPM1 mutations have been described, most of which are technically challenging and require additional laboratory equipment. We developed and validated an assay that allows specific, rapid, and simple screening for NPM1 mutations. FAST PCR spanning exons 8 to 12 of the NPM1 gene was performed on 284 diagnostic AML samples. PCR products were visualized on a 2 % agarose E-gel and verified by direct sequencing. The FAST PCR screening method showed a specificity and sensitivity of 100 %, i.e., all mutated cases were detected, and none of negative cases carried mutations. The limit of detection was at 5-10 % of mutant alleles. We conclude that the FAST PCR assay is a highly specific, rapid (less than 2 h), and sensitive screening method for the detection of NPM1 mutations. Moreover, this method is inexpensive and can easily be integrated in the routine molecular diagnostic work-up of established risk factors in AML using standard laboratory equipment.
Introduction
In acute myeloid leukemia (AML), an increasing number of genetic alterations have been described to be involved in the pathogenesis of the disease, and to determine the phenotype and the impact of the treatment [1] . As a consequence, the identification of molecular alterations by cytogenetic and/or molecular analysis is of great importance for risk stratification and treatment decisions. Molecular analyses are particularly important in AML patients with a normal karyotype who constitute about half of all AML cases [2] .
NPM1 mutations represent the most frequent alterations in AML, occurring in approximately one third of adult patients with AML, and are associated with a normal karyotype in 85 % of cases [3] . In the 2008 World Health Organization (WHO) classification, AML with mutated nucleophosmin (NPM1) has been defined as a separate provisional entity, and there is increasing evidence that NPM1 mutations represent founder genetic events in AML. Various studies have demonstrated the favorable prognostic impact of NPM1 mutations especially in the absence of a FLT3 ITD [4] [5] [6] [7] [8] .
On the molecular level, NPM1 mutations are insertions that cluster within exon 11 and 12 of the NPM1 gene. The insertions typically consist of 1 or 2 tetranucleotides at nucleotides 956 to 971 (reference sequence NM_002520) corresponding to nucleotides c.860 through c.875 (HGVS nomenclature) [9] . The most prevalent mutation is the 960insTCTG (type A mutation) that is present in approximately 80 % of cases. Rare cases of non-tetrameric insertions and deletions/insertions have been described as well as single cases of 8-bp insertions in exon 11 leading to a truncated protein [10, 11] . All mutations in exon 12 lead to a frame-shift and an elongated protein with loss of the nucleolar localization domain and/or gain of a nuclear export signal resulting in an accumulation of the protein in the cytoplasm. A variety of molecular methods for detecting NPM1 mutations have been described, including PCR amplification and direct sequencing, high-resolution fragment analysis based on a fluorescence-labeled forward primer (Genescan), melting curve analysis on the LightCycler system, denaturing high-performance liquid chromatography (DHPLC), and LNA-mediated PCR clamping [12] . These methods are technically challenging and require well-trained personnel and additional laboratory equipment that might not be available in many molecular routine laboratories. Hence, since the detection of NPM1 mutations at diagnosis is important for risk stratification and treatment decision, molecular laboratories should be able to perform the initial analysis using their standard laboratory equipment. We therefore developed a rapid and simple screening assay based on FAST PCR amplification and standardized agarose gel electrophoresis.
Materials and methods

Patient samples
We validated our assay on 284 diagnostic samples from adult patients with AML referred to our laboratory, including 158 NPM1-mutated (NPM1-mt) samples and a series of 126 in-house NPM1-wild-type (NPM1-wt) 
Mutational analysis
Total RNA was extracted from Ficoll-separated mononuclear cells using the QIAmp RNA Blood Mini Kit (Qiagen, Hombrechtikon, Switzerland) and reverse transcribed by the Superscript II system (Invitrogen, Lucerne, Switzerland). For mutational analysis, a primer pair was designed to amplify exons 8 to 12 of the NPM1 gene (NPM663F 5′-GCGCCAGT-GAAGAAATCTATAC-3′ and NPM1109R 5′-GGACAA-CATTTATCAAACACGG-3′) yielding a 446-bp product. Two microliters of cDNA were amplified in a volume of 20 μl containing 0.5 μM of each primer and 10 μl of 2× GeneAmp Fast PCR Master Mix (Applied Biosystems, Rotkreuz, Switzerland) on a 9800 or Veriti Fast Thermal Cycler (Applied Biosystems). Reaction conditions consisted of an initial denaturation step at 94°C for 10 s followed by 35 cycles at 94°C for 0 s, 60°C for 5 s, and 72°C for 20 s and a final elongation step at 72°C for 30 s. PCR products were run for 40 min on a 2 % agarose E-gel (Invitrogen) where a double band indicates a mutation and a single band represents the wild-type sequence. All PCR products were verified by direct sequencing in both directions using BigDye Terminator Mix version 3 (Applied Biosystems, Rotkreuz, Switzerland) on an ABI3130xl automated sequencer. PCR products yielding a small smear above the wild-type band were sequenced with primers NPM793F (5′ -AAAACTCCTAAAACAC CAAAAGGACC-3′), NPM883F (5′-AAAGTGGAAGC CAAATTCATCAA-3′), NPM845R (5′-CACCTTTTTCTA TACTTGTTGCATTT-3′), and NPM964R (5′-TATTTTCT TAAAGAGACTTCCTCCA-3′).
With FAST PCR, thermal cycling reactions that normally take over an hour and a half can take as little as 25 min. The FAST PCR technique is performed on designated FAST PCR thermal cyclers and optimized reagents must be used. Alternatively, our PCR protocol was also run by standard conditions on an ABI 9700 Thermal Cycler (Applied Biosystems) using Roche Taq polymerase (Roche, Rotkreuz, Switzerland) and buffer. Reaction conditions consisted of denaturation at 95°C for 5 min, 35 cycles at 95°C for 30 s, 60°C for 30 s, and 72°C for 45 s and a final elongation at 72°C for 5 min. Results were consistent, but PCR products were somewhat fainter probably due to a lower PCR efficiency.
Statistical analysis
Statistical analyses were performed on SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois). The nonparametric Wilcoxon-Mann-Whitney test was used for continuous data and the χ 2 or Fisher exact (whenever an expected value was <5) test for categorical data to compare demographic, laboratory and molecular parameters between the patient groups. A p value of <0.05 was considered statistically significant.
Results
Of 284 AML samples included in the study, 158 were NPM1 mutated and 126 were wild-type as determined by FAST PCR screening. Mutated PCR products invariably showed two distinct bands on agarose gel electrophoresis, probably based on heteroduplex formation (Fig. 1) . All mutated and wild-type PCR products were directly sequenced in both directions, and the results were 100 % concordant with the screening method. Mutations included 151 typical 4-bp insertions and 6 uncommon mutations in exon 12 ( Table 2 ). In addition, a 19-bp deletion was detected in exon 9 outside the commonly mutated region leading to a frame-shift and a premature stop codon. 1 2 3 4 5 6 7 8 9 10 Fig. 1 After FAST PCR, PCR products are visualized on a 2 % agarose E-gel, where a double band indicates a mutation and a single band represents the wildtype sequence. Lanes 1 100 bp ladder, 2, 3 and 7 patient samples with wild-type NPM1, 4-6 patient samples with mutated NPM1, 8 positive control cell line OCI-AML3, 9 wild-type control cell line HL60, 10 no template control In 2 samples with mutated and 10 samples with wildtype NPM1, a novel 3-bp in frame-deletion in exon 8 (748delTCA) was identified resulting in a loss of serin 218 (p.Ser218del). We detected this sequence variation in samples of patients with other hematological malignancies and healthy donors at variable proportions (CML, 0/18; ALL, 3/18; CLL, 5/12; healthy donors, 14/15) suggesting to represent a common polymorphism. The frequency and potential relevance of this sequence variation is currently under investigation in our laboratory.
Specificity and sensitivity of FAST PCR screening
The specificity and diagnostic sensitivity of the FAST PCR screening method were 100 %, i.e., all positive samples carried mutations and none of the 126 negative cases were mutated (positive predictive value of 1.00 and negative predictive value of 1.00). The limit of detection (LOD) of the assay as assessed by serial dilution experiments of the cell line OCI-AML3 in the negative cell line HL60 was 5-10 % mutated alleles.
NPM1 mutations and biological and morphological features
The incidence of NPM1 mutations was higher in women (NPM1-mt, women, n086 (54 %); men n072; NPM1-wt, women, n049 (39 %), men n077, p00.009). The median ages of patients with and without NPM1 mutations were 58 and 56 years, respectively. Patients with NPM1 mutations had significantly higher median white blood cell counts than patients without NPM1 mutations (26.3 × 10 9 /L versus 6.6×10 9 /L; p<0.0005). No difference was observed with regard to the peripheral blast count (NPM1-mt, median, 40.5; NPM1-wt, median, 39.5). NPM1 mutations were predominantly found in the French-American-British (FAB) subgroups M1, M2, M4, and M5, and were less frequent in M0, M6, and M7. When compared to the NPM1-wt group, NPM1 mutations were significantly less frequent in FAB M0 and more frequent in FAB M5 (FAB M0, 2.2 % versus 19.7 %; p<0.0005; FAB M5, 25.2 % versus 3.3 %; p<0.0005).These data confirm the known features of many reports reviewed in [3] .
NPM1 mutations and cytogenetic and molecular features
Cytogenetic data were available for 257 of the 284 patients with AML. In accordance with results from other studies, NPM1 mutations were significantly associated with a normal karyotype (NPM1-mt, 80.9 %; NPM1-wt, 48.4 %; p< 0.0005) [3] . Patients with an aberrant karyotype were classified in cytogenetic risk groups according to the recommendations of the European LeukemiaNet [13] . We found significantly less patients with NPM1 mutations in the favorable and adverse cytogenetic subgroups compared to patients without NPM1 mutations (favorable, 0 versus 7.9 %; p00.001; adverse, 5.3 % versus 32.5 %; p00.001); 13.7 % and 11.1 % of patients with and without NPM1 mutations carried chromosomal aberrations of type 
Discussion
Given the favorable prognostic value of the NPM1+/ FLT3 ITD− genotype and the resulting therapeutic consequences, a rapid and simple method to assess the presence of NPM1 mutations is required. In this report, we show that FAST PCR and subsequent gel electrophoresis is a specific and robust tool for the screening of NPM1 mutations and can be performed in less than 2 h. PCR products are run on a ready-to-use 2 % agarose gel that clearly separates the mutant from the wild-type band. The remaining PCR product can directly be sequenced for accurate determination of the type of mutation. Although the prognostically favorable phenotype of NPM1 mutations is independent of the type of mutation, it is important to identify the precise mutation for the design of real-time primers and probes for subsequent monitoring of minimal residual disease by qPCR. In contrast to other methods, both the specificity and diagnostic sensitivity of the FAST PCR screening assay are 100 % (methods reviewed in [12] ). The LOD of 5-10 % mutated alleles equals the sensitivity of other methods such as capillary electrophoresis and is higher than for direct sequencing. For minimal residual disease detection, more sensitive methods such as allele-specific qPCR are appropriate, yet at the price of a limited diagnostic sensitivity that is restricted to one specific mutation per assay.
The FAST PCR technique has the advantage of reducing time-to-results by approximately a half to two thirds. Many but not all standard PCR protocols can be converted with little effort. The protocol presented in this report can also be run with standard conditions but yields the most PCR product by the FAST PCR mode.
We conclude that FAST PCR followed by agarose gel electrophoresis allows highly specific, rapid and sensitive screening for NPM1 mutations. More precisely, all mutations were detected and none was missed by this method. In addition, our assay is inexpensive and can easily be integrated in the routine molecular diagnostic work-up of established risk factors in AML using standard laboratory equipment.
